UMIT Private University for Health Sciences Medical Informatics and Technology: Results of a Collaborative Study at Campus Tyrol Argue in Favor of a Personalized Prostate Cancer Screening Approach

Food and Healthcare Press Releases Tuesday July 4, 2017 09:00
HALL, Austria--4 Jul--PRNewswire/InfoQuest

A simulation study published in BMC Public Health by researchers of the Tyrolean Health and Life Sciences University UMIT, the Oncotyrol center, the Medical University of Innsbruck and the University of Toronto highlights optimized use of prostate cancer screening.

(Photo: http://mma.prnewswire.com/media/529873/UMIT_Dr_Uwe_Siebert.jpg )
(Photo: http://mma.prnewswire.com/media/529874/UMIT_Nikolai_Muhlberger.jpg )

"Like most medical procedures also screening harbors benefits and risks. This gains increasing attention by the public," explains Prof. Dr. Uwe Siebert, Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT and President-Elect of the Society for Medical Decision Making. "A major risk of prostate cancer screening is that of overdiagnosis and overtreatment. This refers to the diagnosis and treatment of clinically irrelevant tumors, which would not cause any complaints during men's lifetime and remain undetected without screening. Currently, there is no reliable method to distinguish clinically relevant from clinically irrelevant tumors. In consequence, also clinically irrelevant tumors may be treated, which unnecessarily exposes the affected patients to the unfortunately not uncommon long-term treatment complications such as erectile dysfunction, incontinence, bowel dysfunction."

The simulation model developed by the researchers within a ONCOTYROL research project for personalized medicine simulates the positive and negative effects of screening on the duration and quality of life of screening participants and analyses under which circumstances the potential harms of screening outweigh the potential benefits. Project Coordinator Ass. Prof. Dr. Nikolai Muhlberger summarizes the study findings as follows: "The study results suggest that participation in screening reduces the risk to die from prostate cancer and prolongs the life expectancy of participating men. However, when quality-of-life effects are considered as well, it is shown that primarily men with elevated familial prostate cancer risk benefit from screening, while in men with average prostate cancer risk overall the harms of screening prevail. In addition, the simulation predicts that the benefit of screening in men with elevated familial risk also strongly depends on their individual valuation of treatment-related long-term side-effects."

The urological experts in the research team, Prof. Dr. Wolfgang Horninger und Prof. Dr. Helmut Klocker, see the study as an important contribution towards a targeted application of prostate cancer screening. Horninger, the Dean of the Department of Urology at the Medical University of Innsbruck explains: "The study highlights the problem of overdiagnosis and illustrates the dependency of screening benefits on individual risk factors and preferences. Thus, it contributes to the improvement of patient counseling and supports an individual use of screening examinations, which all of us consider as important issues."

Contact: Prof. Dr. Uwe Siebert,   public-health@umit.at , +4350-8648-673930
Source: UMIT - The Health & Life Sciences University

Latest Press Release

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

- First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is...

Terumo BCT Expands Collaboration With Mallinckrodt to Bring More Treatment Options to Patients

Expanded collaboration will bring a specialized treatment option to more patients who can be helped with extracorporeal photopheresis (ECP) to treat certain immune-mediated diseases Terumo BCT, a global leader in blood component, therapeutic apheresis...

Identifying extreme impact in research, Clarivate Analytics uses citations to forecast Nobel Prize winners

Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced its 2017 Citation Laureates. Each year since 2002, analysts at Clarivate Analytics have mined millions of citations...

Institut Marques presents their studies on music and the beginning of life at the Massachusetts Institute of Technology

- Dr. Marisa Lopez-Teijon, director of this internationally renowned center in Assisted Reproduction, has received the Ig Nobel Prize for Medicine - The awards, held at Harvard University, recognize the most surprising and innovative scientific...

Asate AG: Great Honor for Swiss Therapist in America as Snoring and Sleep Apnoea Researcher Alex Suarez Receives Ig-Nobel Prize

For millions of suffering people, a dream has finally come true: to be able to sleep without snoring. The unconventional innovation of successful Swiss Therapist, Alex Suarez (50), has solved the problem once and for all, and out of 9,000 nominations it...

Related Topics